Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10447084 | 0.97 | HRH3 (0.47) | HRH3USP2KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL34472404 | 0.92 | USP2 (0.44) | HRH3USP2KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL536772 | 0.88 | USP2 (0.50) | HRH3USP2KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL12937 | 0.86 | ALDH1A1 (0.54) | HRH3USP2KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL13019 | 0.82 | KDM4E (0.56) | HRH3USP2KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL7007038 | 0.82 | HRH3 (0.50) | HRH3KDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL348065 | 0.82 | HRH3 (0.50) | HRH3KDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL1799442 | 0.82 | HRH3 (0.50) | HRH3KDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL13334891 | 0.79 | KEAP1 (0.48) | HRH3USP2KDM4EKEAP1SMN1; SMN2 | |
| SCHEMBL11228957 | 0.79 | HRH3 (0.47) | HRH3USP2KDM4EKEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104193698-A | Synthesis method of N-(4-methyl morpholine)-piperidine | YANTAI HENGDIKE ENERGY TECHNOLOGY CO LTD | 2014-12-10 | — | — | CN | claimed |
| US-20230293517-A1 | ANTAGONIST COMPOUNDS | JANSSEN PHARMCEUTICA NV (BE) | 2023-09-21 | — | — | US | disclosed |
| CN-108473429-B | ROR gamma modulators | 领先制药控股公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3303291-B1 | ROR-GAMMA MODULATORS | LEAD PHARMA B V (NL) | 2020-03-18 | — | — | EP | disclosed |
| US-10315996-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-06-11 | — | — | US | disclosed |
| CN-108473429-A | ROR gamma modulators | 领先制药控股公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20180170877-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-21 | — | — | US | disclosed |
| EP-3303291-A1 | ROR GAMMA (ROR ) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | disclosed |
| US-9708269-B2 | Process for making isoquinoline compounds | FIBROGEN, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016193452-A1 | ROR GAMMA (RORγ) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | disclosed |
| EP-2032140-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-03-11 | — | — | EP | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| WO-2008090379-A1 | PYRAZOLOQUINAZOLINONES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-31 | — | — | WO | disclosed |
| WO-2007138355-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-06 | — | — | WO | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| CN-1976922-A | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| CN-1230421-C | Amide compound and pharmaceutical use thereof | MITSUBISHI CHEM CORP (JP) | 2005-12-07 | — | — | CN | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| CN-1346348-A | Amide compound and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2002-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315996-B2 | ROR gamma (RORγ) modulators | RORA, RORB, RORC | HRH3 226/4885USP2 3803/4885KDM4E 2199/4885 |
| US-20230293517-A1 | ANTAGONIST COMPOUNDS | ADORA2B, ADORA2A, ADORA1 | HRH3 164/4885USP2 4118/4885KDM4E 3858/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | HRH3 1003/4885USP2 4022/4885KDM4E 1813/4885 |
| US-20180170877-A1 | ROR GAMMA (RORY) MODULATORS | RORA, RORB, RORC | HRH3 185/4885USP2 3816/4885KDM4E 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.